palbociclib - Profile

What are the generic sources for palbociclib and what is the scope of freedom to operate?

Palbociclib is the generic ingredient in two branded drugs marketed by Pfizer and Zydus Lifesciences, and is included in three NDAs. There are three patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Palbociclib has one hundred and sixty-nine patent family members in fifty-six countries.

There are nine tentative approvals for this compound.

Summary for palbociclib

International Patents:	169
US Patents:	3
Tradenames:	2
Applicants:	2
NDAs:	3
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for palbociclib

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for palbociclib

Constraining patent/regulatory exclusivity:

10,723,730*PED

Dosage:

CAPSULE;ORAL

Constraining patent/regulatory exclusivity:

11,065,250*PED

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Generic filers with tentative approvals for PALBOCICLIB

Applicant	Application No.	Strength	Dosage Form
		100MG	CAPSULE
		125MG	CAPSULE
		125MG	CAPSULE;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Paragraph IV (Patent) Challenges for PALBOCICLIB

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
IBRANCE	Tablets	palbociclib	75 mg, 100 mg and 125 mg	212436	1	2020-11-24
IBRANCE	Capsules	palbociclib	75 mg, 100 mg and 125 mg	207103	12	2019-02-04

US Patents and Regulatory Information for palbociclib

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	IBRANCE	palbociclib	CAPSULE;ORAL	207103-001	Feb 3, 2015		RX	Yes	No	RE47739*PED				Y
Pfizer	IBRANCE	palbociclib	CAPSULE;ORAL	207103-001	Feb 3, 2015		RX	Yes	No	10,723,730*PED				Y
Pfizer	IBRANCE	palbociclib	CAPSULE;ORAL	207103-001	Feb 3, 2015		RX	Yes	No
Pfizer	IBRANCE	palbociclib	CAPSULE;ORAL	207103-001	Feb 3, 2015		RX	Yes	No

Expired US Patents for palbociclib

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pfizer	IBRANCE	palbociclib	CAPSULE;ORAL	207103-003	Feb 3, 2015	7,208,489
Pfizer	IBRANCE	palbociclib	TABLET;ORAL	212436-002	Nov 1, 2019	6,936,612
Pfizer	IBRANCE	palbociclib	CAPSULE;ORAL	207103-003	Feb 3, 2015	7,456,168
Pfizer	IBRANCE	palbociclib	CAPSULE;ORAL	207103-002	Feb 3, 2015	7,456,168

EU/EMA Drug Approvals for palbociclib

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Pfizer Europe MA EEIG	Ibrance	palbociclib	EMEA/H/C/003853Ibrance is indicated for the treatment of hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer:in combination with an aromatase inhibitor;in combination with fulvestrant in women who have received prior endocrine therapy.In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone releasing hormone (LHRH) agonist.	Authorised	no	no	no	2016-11-09

International Patents for palbociclib

Country	Patent Number	Title	Estimated Expiration
Argentina	094842
Australia	2014220354
Brazil	112015019508
Canada	2900322

Supplementary Protection Certificates for palbociclib

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1470124	132017000046148	Italy		PRODUCT NAME: PALBOCICLIB, OPZIONALMENTE NELLA FORMA DI UN SALE, ESTERE, AMMIDE O PROFARMACO FARMACEUTICAMENTE ACCETTABILE(IBRANCE); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/16/1147/001-006, 20161111
1470124	CA 2017 00010	Denmark		PRODUCT NAME: PALBOCICLIB, EVENTUELT I FORM AF EN FARMACEUTISK ACCEPTABEL ESTER ELLER ET FARMACEUTISK ACCEPTABELT SALT, AMID ELLER PRODRUG; REG. NO/DATE: EU/1/16/1147/001-006 20161111
1470124	122017000014	Germany		PRODUCT NAME: PALBOCICLIB, OPTIONAL IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, ESTERS, AMIDES ODER EINES PRODRUGS HIERVON; REGISTRATION NO/DATE: EU/1/16/1147 20161109
1470124	614	Finland

Palbociclib: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

Executive Summary

Palbociclib (brand name Ibrance), developed by Pfizer, is a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor for treating hormone receptor-positive (HR+), HER2-negative advanced or metastatic breast cancer. Since its FDA approval in 2015, palbociclib has become a cornerstone in targeted breast cancer therapy, with expanding indications and global adoption fueling its revenue growth. This report analyzes the current investment scenario, market dynamics, and projected financial trajectory, with a focus on competitive landscape, regulatory environments, and pipeline developments.

Summary of Key Data Points

Parameter	Value	Source
Global Market Size (2022)	$2.3 billion	Grand View Research [1]
Expected CAGR (2022-2030)	8.2%	Statista [2]
Pfizer’s 2022 Revenue (Palbociclib segment)	~$1.9 billion	Pfizer Annual Report [3]
Major Competitors	Abemaciclib (Lilly), Ribociclib (Novartis)	Market reports
Number of Approvals	7 countries (including US, EU, Japan)	Regulatory filings
Pipeline Candidates	3+ (investigating other cancers)	ClinicalTrials.gov

---

What is the Current Investment Outlook for Palbociclib?

Market Positioning and Revenue Streams

Palbociclib's entrenched position in HR+/HER2- breast cancer treatment provides a solid revenue base. Key revenue drivers include:

• First-line and subsequent-line therapy sales
  Recently, expanding indications have included early-stage settings, contributing to revenue diversification.

• Global market penetration
  North America accounts for approximately 55% of sales; Europe and Asia are growing markets.

• Pricing strategies
  High-cost therapy (annual prices ~$10,000–$15,000 per patient in the US) with varying reimbursement landscapes.

Growth Factors

• Growing breast cancer incidence
  Approximately 2.3 million new cases globally in 2020, with a significant proportion HR+/HER2- subtype.

• Expanding indications
  Ongoing trials exploring adjuvant use and combination therapies.

• Pipeline development
  Focused on overcoming resistance and extending indications into other cancers, such as lung and ovarian.

Investment Risks

• Patent expiry and biosimilar competition
  Patents expected to last until 2030 in major markets; biosimilars not yet on the horizon, but potential entry risk exists.

• Competitive resistance
  Efficacy may diminish over time; resistance mechanisms are under active study.

• Pricing pressures
  Increasing scrutiny over drug prices could impact margins.

---

Market Dynamics Impacting Palbociclib

Competitive Landscape

Competitor	Drug Name	Status	Market Share	Key Differentiation
Eli Lilly	Abemaciclib	Approved; launched	~20% (globally)	Continuous dosing, less myelosuppression
Novartis	Ribociclib	Approved; launched	~15%	Favorable safety profile
Pfizer	Palbociclib	Primary product	~55%	First-mover advantage, broad indications

Regulatory & Reimbursement Environment

• FDA and EMA approvals facilitate market access.
• Pricing and reimbursement policies tailored to regional healthcare systems influence sales growth.
• Orphan drug status granted in certain jurisdictions for specific indications, providing market exclusivity.

Emerging Therapies & Pipeline Competition

• Novel CDK4/6 inhibitors with improved safety profiles or oral bioavailability.
• Combination therapies with immunotherapy or targeted agents.
• Potential for biosimilar entry post-patent expiry.

Market Penetration Drivers

• Adoption in early-line therapy.
• Incorporation into comprehensive breast cancer treatment guidelines.
• Expansion into developing economies with rising healthcare infrastructure.

---

Financial Trajectory Projections

Revenue Forecast (2023-2030)

Year	Projected Revenue (USD billions)	Assumptions	Source/Modeling
2023	$2.4 billion	Continued adoption, expanding indications	Analyst consensus
2025	$3.2 billion	Market expansion, pipeline success	Compound CAGR 8.2%
2030	$4.8 billion	Broadening pipeline, global reach	Market trends

Profitability and Margin Analysis

• Current gross margin estimated at 75%, driven by high drug pricing and stable production costs.
• Research and Development (R&D) investment remains significant (~15% of revenue) due to pipeline activities.
• Market share retention critical; loss of exclusivity could reduce margins unless offset by new indications.

Investment Opportunities

• Early investment in pipeline candidates focusing on other tumor types.
• Partnerships with regional manufacturers to expand global footprint.
• Development of biosimilars post-patent expiration offers new revenue streams.

---

Comparison with Competitors and Similar Oncology Drugs

Drug	Indication	Market Share (2022)	Patent Expiry	Pipeline Status	Key Strengths	Challenges
Palbociclib	HR+/HER2- breast cancer	55%	2030	Multiple trials	First approved, broad indications	Resistance mechanisms
Abemaciclib	HR+/HER2- breast cancer	20%	2028	Expanding indications	Continuous dosing	Safety concerns on diarrhea
Ribociclib	HR+/HER2- breast cancer	15%	2029	Some trials	Favorable safety profile	Smaller market share
Other CDK4/6 inhibitors	Various	10%	N/A	Pipeline (early-stage)	Potential breakthroughs	Market entry barriers

---

Key Market Drivers & Challenges

Drivers

• Growing prevalence of HR+ breast cancer.
• Clinical guideline endorsements for CDK4/6 inhibitors.
• Combination therapy approvals increasing treatment options.
• Global health initiatives improving cancer screening, leading to early diagnoses.

Challenges

• Pricing and reimbursement constraints in cost-sensitive markets.
• Biosimilar and generic competition post-patent expiry.
• Emerging resistance mechanisms reducing long-term efficacy.
• Regulatory delays impacting pipeline progression.

---

Regulatory Environment & Policy Landscape

Region	Regulatory Body	Approvals	Market Access Challenges	Notes
US	FDA	Approved 2015	Reimbursement variability	CMS policies influence pricing
EU	EMA	Approved 2016	Price negotiations	HTA agencies impact launches
Japan	PMDA	Approved 2017	Cost containment measures	Government reimbursement limits

Pipeline and Future Indications

Candidate	Indication	Trial Phase	Expected Approval Year	Notes
PF-06873600	Ovarian, Lung	Phase 2	2024-2025	Expansion into other cancers
Combination trials	Multiple	Phase 3	2026	Immunotherapy + CDK4/6 inhibitors
Adjuvant setting	Breast cancer	Phase 3	2027	Early-stage disease

---

Deep-Dive: Investment Risks and Reward Balance

Risk	Impact	Mitigation Strategies	Status
Patent expiration	Revenue decline	Pipeline expansion	Medium-term threat
Competitive innovation	Market share erosion	R&D focus	Active
Regulatory hurdles	Delays in revenue	Pre-approval studies	Managed
Pricing pressures	Margin squeeze	Value-based pricing models	Ongoing

---

Conclusion

Palbociclib remains a high-value asset with robust sales prospects driven by global breast cancer treatment growth, expanding indications, and pipeline advancements. The competitive landscape will tighten with early-stage rivals and biosimilars post-2030, but strategic investments in pipeline and regional expansion can sustain growth. Regulatory stability and favorable reimbursement policies are critical to maximizing financial outcomes.

Key Takeaways

• Strong Market Position: Palbociclib commands a dominant share in the growing HR+ breast cancer segment, with an established brand and regulatory approval in key markets.
• Growth Potential: Revenue CAGR forecasted at approximately 8.2%, driven by expanding indications and global access.
• Pipeline Significance: Investment in pipeline candidates is essential for long-term growth beyond patent expiry, especially in related cancers.
• Competitive Risks: Biosimilar entry and resistance mechanisms threaten margin sustainability; ongoing innovation mitigates this.
• Regulatory & Pricing Risks: Variability across regions necessitates adaptive market strategies to optimize revenue.

---

FAQs

1. What factors influence the market longevity of palbociclib?
Market longevity depends on patent protection duration, pipeline success, competitive innovations, and regulatory/regimen approvals in emerging indications.

2. How does palbociclib compare financially with its competitors?
Its market share (~55%) and established efficacy position it favorably, though competitors like abemaciclib and ribociclib are gaining traction with differentiated safety profiles.

3. What is the impact of biosimilars on palbociclib’s future revenue?
Biosimilars are unlikely until patent expiry (~2030). Post-expiry, biosimilar entry could significantly reduce pricing power.

4. Are there emerging indications that could extend palbociclib’s market?
Yes, ongoing trials aim to approve palbociclib for adjuvant therapy and other cancers like lung and ovarian, potentially broadening revenue streams.

5. How do regulatory policies affect palbociclib’s commercial prospects?
Regulatory approvals in major markets facilitate sales, while regional reimbursement policies and HTA decisions influence accessibility and pricing.

---

References

1. Grand View Research, "Cancer Drugs Market Size & Trends," 2022.
2. Statista, "Global Oncology Market Forecast," 2022.
3. Pfizer Annual Report, 2022.